Approaches to the treatment of autosomal-dominant spinocerebellar ataxias
https://doi.org/10.25789/YMJ.2025.92.24
Abstract
The article is devoted to the prospects for the treatment of neurodegenerative diseases with dynamic mutations based on published studies of the search for approaches to the treatment of spinocerebellar ataxia. Although these diseases are incurable, research results show that certain medications and physical therapy can alleviate the symptoms of cerebellar ataxia. Due to the progress made in the study of spinocerebellar ataxia in recent years, there are high hopes that it will be possible to develop gene therapy methods that will slow down the progression of the disease or even stop its development.
References
1. Gorbunova V.N., Baranov V.S. Introduction to molecular diagnostics and gene therapy of hereditary diseases //St. Petersburg: "Special literature", 1997. 278s.
2. 3,5-Dimethyl-adamantane-1-amine restores short-term synaptic plasticity by changing the function of excitatory amino acid transporters in model mice with type 1 spinocerebellar ataxia / O.S. Belozor, A.A. Vasiliev, A.G. Mileyko [et al.] // Annals of Clinical and Experimental Neurology. 2024, V. 18. N 1. P.63-71. DOI: https://doi.org/10.54101/ACEN.2024.1.7
3. Kononova S.K. The introduction of genetic technologies into practical healthcare in Yakutia on the example of type 1 spinocerebellar ataxia in the context of translational medicine // Yakut Medical Journal. 2022.T.3.N79. P. 103-107.
4. Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease / S. Alves, I. Nascimento-Ferreira, G. Auregan [et al.] // PLoS One. 2008; 3(10): e3341. doi: 10.1371/journal.pone.0003341.
5. A Mild PUM1 Mutation Is Associated with Adult-Onset Ataxia, whereas Haploinsufficiency Causes Developmental Delay and Seizures / V.A. Gennarino, E.E. Palmer, L.M. McDonell [et al.] // Cell. 2018 Feb 22;172(5):924-936.e11. doi: 10.1016/j.cell.2018.02.006.
6. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD / P.M. Switonski, W.J. Szlachcic, W.J. Krzyzosiak [et al.] // Neurobiol Dis. 2015;73:174-88. doi: 10.1016/j.nbd.2014.09.020.
7. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2 / D.R. Scoles, P. Meera, M.D. Schneider [et al.] // Nature. 2017;544(7650):362-366. doi: 10.1038/na-ture22044.
8. Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1 / R. Hourez, L.Servais, D. Orduz [et al.] // J Neurosci. 2011; 31(33):11795-807. doi: 10.1523/JNEUROS-CI.0905-11.2011.
9. A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action / K.S. Makarova, N.V. Grishin, S.A. Shabalina [et al]// Biol Direct. 2006;1(1):1-26. doi: 10.1186/1745-6150-1-7.
10. Autophagy, aging, and age-related neurodegeneration /J.E. Palmer, N. Wilson, S.M. Son [et al.] // Neuron. 2025;113(1):29-48. doi: 10.1016/j.neuron.2024.09.015.
11. A(2A) Adenosine Receptor Antagonists in Neurodegenerative Diseases / M. Pohanka, P.A. Borea, K. Varani [et al.]// Curr Med Chem. 2022;29(24):4138-4151. doi:10.2174/0929867328666211129122550.
12. Brain changes associated with postural training in patients with cerebellar degeneration: a voxel-based morphometry study/ R.G. Bur-ciu, N. Fritsche, O. Granert [et al.] // J Neurosci. 2013;33(10):4594-604. doi: 10.1523/JNEUROS-CI.3381-12.2013.
13. Burnett B, Li F, Pittman RN. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity // Hum Mol Genet. 2003;12(23):3195-205. doi: 10.1093/hmg/ddg344.
14. Cardoso SV, Fernandes SR, Tomas MT. Therapeutic Importance of Exercise in Neuroplasticity in Adults with Neurological Pathology: Systematic Review// Int J Exerc Sci. 2024;17(1):1105-1119. doi: 10.70252/VZWF7949.
15. Cerebellar TMS in treatment of a patient with cerebellar ataxia: evidence from clinical, biomechanics and neurophysiological assessments/ F. Farzan, Y. Wu, B. Manor [et al.] // Cerebellum. 2013;12(5):707-12. doi: 10.1007/s12311-013-0485-8.
16. Cerebellar Transcranial Direct Current Stimulation in Spinocerebellar Ataxia Type 3: a Randomized, Double-Blind, Sham-Controlled Trial / RPPWM Maas, S. Teerenstra, I.Toni [et al.] // Neurotherapeutics. 2022;19(4):1259-1272. doi: 10.1007/s13311-022-01231-w.
17. Cerebellar Neurostimulation for Boosting Social and Affective Functions: Implications for the Rehabilitation of Hereditary Ataxia Patients. / A. Ciricugno, V. Oldrati, Z. Cattaneo [et al.] // Cerebellum. 2024;23(4):1651-1677. doi: 10.1007/s12311-023-01652-z.
18. Clinical Characteristics and Possible Drug Targets in Autosomal Dominant Spinocerebellar Ataxias / L. Szpisjak, D. Zadori, P. Klivenyi [et al.] // CNS Neurol Disord Drug Targets. 2019;18(4):279-293. doi: 10.2174/1871527318666190311155846
19. Contribution of L-type channels to Ca2+ regulation of neuronal properties in early developing purkinje neurons / D.L. Gruol, J.G. Netzeband, L.A. Quina [et al.] //Cerebellum. 2005;4(2):128-39. doi: 10.1080/14734220510007969.
20. Changing Brain Networks Through Non-invasive Neuromodulation/ W.T. To, D. De Ridder, J. Jr. Hart [et al.]// Front Hum Neurosci. 2018 ;12:128. doi: 10.3389/fnhum.2018.00128.
21. Gowing G, Svendsen S, Svendsen CN. Ex vivo gene therapy for the treatment of neurological disorders// Progr Brain Res. 2017; 230:99132. doi: 10.1016/bs.pbr.2016.11.003.
22. CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells / Ouyang S, Xie Y, Xiong Z [et al.] // Stem Cells Dev. 2018;27(11):756-770. doi: 10.1089/scd.2017.0209.
23. CRISPR/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells/ L. He, S. Wang, L. Peng [et al.] // Transl Psychiatry. 2021;11(1):479. doi: 10.1038/s41398-021-01605-2.
24. CRISPR/Cas9-mediated genetic correction reverses spinocerebellar ataxia 3 disease-associated phenotypes in differentiated cerebellar neurons/ G. Song, Y. Ma, X.Gao [et al.] // Life Med. 2022;1(1):27-44. doi: 10.1093/lifemedi/lnac020.
25. Cross-talking noncoding RNAs contribute to cell-specific neurodegeneration in SCA7 / J.Y. Tan, K.W. Vance, M.A. Varela [et al.] // Nat Struct Mol Biol. 2014;21(11):955-961. doi: 10.1038/nsmb.2902.
26. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation/ G. Schaffar, P. Breuer, R. Boteva [et al.] // Mol Cell. 2004;15(1):95-105. doi: 10.1016/j.molcel.2004.06.029.
27. Deglon N. Gene editing as a therapeutic strategy for spinocerebellar ataxia type-3// Rev Neurol (Paris). 2024;180(5):378-382. doi: 10.1016/j.neurol.2024.03.003.
28. Effect of a Home-Base Core Stability Exercises in Hereditary Ataxia. A Randomized Controlled Trial. A Pilot Randomized Controlled Trial / R. Cabanas-Valdes, H. Fernandez-Lago, S. Pelaez-Hervas [et al.] // Mov Disord Clin Pract. 2024;11(6):666-675. doi: 10.1002/mdc3.14036.
29. Frederick PM, Simard MJ. Regulation and different functions of the animal microR-NA-induced silencing complex// Wiley Interdis-cip Rev RNA. 2022;13(4):e1701. doi: 10.1002/wrna.1701.
30. Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias/ R.A.M. Buijsen, L.J.A. Toonen, S.L. Gardiner [et al.]// Neurotherapeutics. 2019 ;16(2):263-286. doi: 10.1007/s13311-018-00696-y.
Review
For citations:
Kononova S.K. Approaches to the treatment of autosomal-dominant spinocerebellar ataxias. Yakut Medical Journal. 2025;(4):113-117. (In Russ.) https://doi.org/10.25789/YMJ.2025.92.24
Views:
31
JATS XML
Email this article 